Antimicrobial Resistance (AMR) is a public health crisis.

Drug-resistant bacteria and fungi are evolving at a rapid pace. Within three decades, these “superbugs,” could kill up to 10 million people each year. Working to Fight AMR seeks to combat this public health crisis by stimulating the production of new antimicrobial medicines. Scientists have developed only one truly novel antibiotic since 1984, and just 1% of medicines in development globally address bacterial infections.

Without effective antibiotics, infections like UTIs will become very difficult to treat, and surgeries and cancer treatment will become even riskier. We have time to change this bleak future; we have time to turn American innovation into life-saving cures; you have time to send a message to Washington today.

The economics of this issue are upside down, but there are smart policies in Congress that could catalyze the creation of new antimicrobials.

We need your help.

Your Voice Can Save Lives

Action in Congress could accelerate the creation of new antimicrobials. To ensure that Washington, D.C. understands the urgency of this crisis, lawmakers need to hear from you. Use this form to easily send a message to your elected representatives and tell them to help stop the spread of superbugs by passing impactful legislation that encourages private sector investment.

Advocate Videos


Latest News

Op-Ed: We’re losing the fight against superbugs, but there’s still hope

As parents, we inherently want to protect our children. We tell them stories with happy endings and reassure them that…

Read More

COVID-19 may have led to a spike in antibiotic resistance

Antibiotic resistance has been on the rise in the United States during the COVID-19 pandemic. A new analysis suggests that…

Read More

Superbug Bulletin, Issue #17

Issue No. 17: Unsettling Trends in the Fight Against Superbugs The COVID-19 pandemic felt like it arrived swiftly, spreading around…

Read More

Antibiotics Venture Fund Makes Its First Two Investments

AMR Action Fund plans to invest $1 billion in startups fighting antibiotic-resistant bugs. Its first bets are on Venatorx and…

Read More

Sign up for the latest on fighting AMR

  • This field is for validation purposes and should be left unchanged.